Jefferies Thinks Medicines Co’s Stock is Going to Recover

By Carrie Williams

Jefferies analyst Eun Yang reiterated a Buy rating on Medicines Co (NASDAQ: MDCO) on September 12 and set a price target of $54. The company’s shares opened today at $33.35, close to its 52-week low of $30.80.

According to, Yang is a 4-star analyst with an average return of 5.8% and a 52.0% success rate. Yang covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, DBV Technologies SA – American, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Medicines Co is Strong Buy and the average price target is $54.50, representing a 63.4% upside.

In a report issued on August 29, Chardan Capital also assigned a Buy rating to the stock.

The company has a one year high of $55.95 and a one year low of $30.80. Currently, Medicines Co has an average volume of 1.16M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on leading acute and intensive care hospitals worldwide. The company markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv.